Back to results

Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (SUNRAY-01)

Objective

To determine the dose of LY3537982 to be administered to patients with NSCLC in combination with pembrolizumab in the Phase 3 portion of the study; To assess the preliminary efficacy of LY3537982 in combination with pembrolizumab To evaluate PROs from the 2 different doses of LY3537982

Protocol #

J3M-MC-JZQB

Trial Phase:

Phase III

Principal Investigator:

Martins, Renato

Cancer Type
  • Lung
Study Site
  • Virginia Commonwealth University

Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease not suitable for curative intent radical surgery
or radiation therapy. Staging will be according to the AJCC Staging System
At least 18 years of age

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Carrie Donovan, RN
    Phone: +1 804-628-3836
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: